Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Valeant buys into Russian OTC market; NicOx buys stake in U.K. ophthalmology firm Altacor; Naturex reaches India coverage; Eurofins purchases BASF test business; Fortitech fortifies Asian presence; more news In Brief.

You may also be interested in...



In Brief

ERSP clarifies requirements for quantified claims; food, veterinary medicine under same FDA office; FDA hosts forum on food safety regs; FDA OKs Reddy’s pediatric Allegra equivalent; Valeant finalizes Natur Produkt acquisition; FTC Chairman Jon Leibowitz to step down.

Fortitech Deal Fills Gap In DSM’s Nutritional Portfolio

DSM’s announcement of its $634 million cash acquisition of Fortitech follows the firm’s report that its nutritional business was the key sales driver in its latest earnings period. Fortitech adds macro-blend manufacturing for human nutritional products to DSM’s supply chain.

Fortitech Deal Fills Gap In DSM’s Nutritional Portfolio

DSM’s announcement of its $634 million cash acquisition of Fortitech follows the firm’s report that its nutritional business was the key sales driver in its latest earnings period. Fortitech adds macro-blend manufacturing for human nutritional products to DSM’s supply chain.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS105667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel